If so, you may be eligible for this study which aims to assess a study drug for treatment-resistant rheumatoid arthritis (RA).
Get StartedYou may be eligible to participate in this study if you:
*‘Refractory’ means your rheumatoid arthritis does not respond to standard treatment options or improve despite trying different medications.
Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.
This study aims to assess the effectiveness of a study drug and how it impacts rheumatoid arthritis symptoms.
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility. Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
PatientWing is helping to identify potential individuals who may be interested in the Frontier Study.
You will have a short call with PatientWing to answer additional questions about your medical history and PatientWing will help collect your medical records.
After your conversation with PatientWing, you will meet the research team who will review your medical records. If the research team thinks you are eligible, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!
After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:
Participation in this study will not come at an additional cost to you. Reasonable expenses such as travel and parking are reimbursed within reasonable limits.
Fill out the questionnaire and provide basic information to express interest in the study. You can also email studies@patientwing.com or call/text: 213-459-2979.
We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!
The study drug will be given as subcutaneous injection once a week.
You will have 20 visits to the research site during the study period.
Your participation may be about 13 months.
No, this study does not have a placebo. You will receive the study drug, blinatumomab, if you participate in the study.
